TrialJournal of hematology & oncology2025

Naxitamab plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for primary refractory high-risk neuroblastoma: results of a phase I/II trial.

Brian H Kushner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.